CatalystFDA/Bio

SCHOLAR ROCK DOWNGRADED AT BARCLAYS DESPITE FDA APPROVAL OF SMA THERAPY - SEEKINGALPHA

Barclays downgrade despite FDA approval of SMA therapy signals conflicting catalysts.

What changed

Barclays downgrade despite FDA approval of SMA therapy signals conflicting catalysts.

Why it matters

Barclays downgrade despite FDA approval of SMA therapy signals conflicting catalysts. — impact context not separately stored; see What changed.

Sources